muscle loss with glp 1 The Hidden Risk Of GLP-1 Medications: And How To Combat It Strategies to prevent loss of

While GLP-1 RAs are powerful tools, preoperative use does not consistently translate into superior long-term postoperative weight loss

doi: 10.1210/endo.133.6.8243312 [DOI] [PubMed] [Google Scholar] 86.Drucker DJ

Great summary of emerging GLP-1 medicines including: triple agonist retatrutide maridebart cafraglutide (MariTide), a long-acting peptide-antibody conjugate that combines GLP-1 receptor agonism with GIP receptor antagonism Amycretin, a unimolecular GLP-1 and amylin receptor agonist, CagriSema - a fixed-dose, once-weekly combination of semaglutide and the long-acting amylin analogue cagrilintide Oral formulations of GLP-1 medicines including orforglipron Fixed-dose combinations of GLP-1 receptor agonists and basal insulin Emerging Indications such as: cardiovascular disease in patients with obesity without diabetes based on the SELECT trial metabolic liver disease based on the ESSENCE trial peripheral artery disease based on STRIDE trial potential indications such as Parkinson disease and dementia Nice summary on muscle loss and muscle composition Great paper

Patients are screened by licensed healthcare providers on the Hims & Hers platform to determine the best treatment

If signs of a severe allergic reaction occur, call 999

Currently, there is a lack of long-term data on the safety of GLP-1 medications while pregnant